Format

Send to

Choose Destination
Acta Derm Venereol. 2015 Jan;95(1):57-61. doi: 10.2340/00015555-1845.

Etanercept reduces symptoms and severity of psoriasis after cessation of cyclosporine therapy: results of the SCORE study.

Author information

1
Department of Dermatology, AOU Policlinico - Vittorio Emanuele, Catania, Italy. cldermct@nti.it.

Abstract

Cyclosporine is an established therapy for psoriasis that provides rapid relief of symptoms but has long-term toxic side effects. The objective of this study was to demonstrate the efficacy of etanercept as replacement therapy for cyclosporine in patients with moderate-to-severe plaque psoriasis. Patients with plaque psoriasis were given cyclosporine 5 mg/kg/day until achievement of PASI50 at which point cyclosporine was tapered to 0 over 6 weeks. At week 6, patients were randomised (1:1) to receive etanercept (50 mg/week) or placebo for an additional 24 weeks. Patients in the etanercept group (n = 58) experienced a reduction of -1.1 in mean PASI score (p = 0.233 vs. cyclosporine) at week 30; patients in the placebo group (n = 62) had mean PASI increase of 3.7 (p < 0.001 vs. cyclosporine). The incidence of patients reporting any adverse events was not significant between groups (77% etanercept, 74% placebo; p = 0.675). Etanercept demonstrated higher efficacy and good tolerability as replacement therapy for cyclosporine in plaque psoriasis.

TRIAL REGISTRATION:

ClinicalTrials.gov NCT00581555.

PMID:
24682319
DOI:
10.2340/00015555-1845
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Medical Journals
Loading ...
Support Center